Propagating a Full Spectrum of Services for ADC Development and Manufacture

The development and manufacture of antibody-drug conjugates (ADCs) requires expertise in both biological drug substance and chemical active pharmaceutical ingredient (API) technologies. The need for contract development and manufacturing organizations (CDMOs) to provide the full spectrum of services for this rapidly growing drug type for enhanced patient treatment is rising. 

CLICK HERE to read the article.

CLICK HERE to learn more about Abzena.

Contributing Authors:

John Manzello, President, Abzena US

Cambell Bunce, Senior Vice President of Scientific Operations, Abzena